With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

Shares of Hims & Hers Health Inc ( HIMS -25.79%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular ...

Hims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to ...